{
    "clinical_study": {
        "@rank": "79110", 
        "arm_group": {
            "arm_group_label": "Imatinib, CML", 
            "description": "Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine population Pharmacokinetics and differences and\n      variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in\n      treatment of chronic myeloid leukemia patients in Iranian population."
        }, 
        "brief_title": "Population Pharmacokinetics of Imatinib in CML Patients in Iran", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Myelogenous Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in\n      this study then population pharmacokinetics parameters is determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient in chronic phase of myeloid leukemia\n\n          -  no liver and renal failure\n\n        Exclusion Criteria:\n\n          -  multiple dug treatment\n\n          -  previous treatment of interferon\n\n          -  patients in blast or accelerated phase"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with approved diagnosis of chronic myeloid leukemia taking Imatinib as treatment"
            }
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146846", 
            "org_study_id": "Kerman-001-FOPPT"
        }, 
        "intervention": {
            "arm_group_label": "Imatinib, CML", 
            "description": "Patients with chronic myeloid leukemia who receive Imatinib as treatment", 
            "intervention_name": "Imatinib", 
            "intervention_type": "Drug", 
            "other_name": "Glivec"
        }, 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cml", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kerman", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Shahid-Bahonar hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Population Pharmacokinetics of Imatinib in CML Patients in Iran", 
        "overall_official": {
            "affiliation": "Department of pharmaceutics, Faculty of pharmacy, Kerman University of medical sciences", 
            "last_name": "ehsan mohajeri, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The influence of patients' characteristic on the pharmacokinetics of Imatinib will be assessd.", 
            "measure": "Percent of changes of AUC, trough Concentration from predicted values", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling are collected on atleast the 30th day of treatment  at the following time: 1 hour before the dose and 1 hour after the dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146846"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kerman University of Medical Sciences", 
            "investigator_full_name": "Ehsan Mohajeri", 
            "investigator_title": "Assistant of Pharmaceutics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Kerman University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kerman University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}